April 14, 2026 a 11:43 am
EW: Fundamental Ratio Analysis - Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a leader in the medical devices sector, focusing on structural heart disease and critical care monitoring solutions. The company has maintained strong market positions internationally. Despite competitive pressures, its diversified portfolio and constant innovation provide resilience.
Fundamental Rating
The overall fundamental rating of Edwards Lifesciences demonstrates moderate performance with room for improvement across categories.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 3 | |
| Return on Equity | 3 | |
| Return on Assets | 5 | |
| Debt to Equity | 2 | |
| Price to Earnings | 1 | |
| Price to Book | 2 |
Historical Rating
Historical data shows the firm's consistency in performance metrics over time.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-04-13 | 3 | 3 | 3 | 5 | 2 | 1 | 2 |
| --- | 0 | 3 | 3 | 5 | 2 | 1 | 2 |
Analyst Price Targets
Analyst consensus indicates a positive outlook with moderate fluctuations between high and low price targets.
| High | Low | Median | Consensus |
|---|---|---|---|
| 110 | 87 | 95 | 96.29 |
Analyst Sentiment
Analysts show a predominantly positive sentiment towards Edwards Lifesciences stock.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 32 | |
| Hold | 16 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Edwards Lifesciences Corporation remains a reputable player in the healthcare industry, with robust products and a strong international presence. Although there are areas for improvement in terms of valuation metrics, its innovative product lines and consistent market demand are key driving forces. Analyst sentiment is largely positive, underscoring confidence in its future growth. Investors may find opportunities for returns, albeit with the need to monitor competitive market dynamics closely.